[{"id":"876779ef-d028-4263-8450-62d8fcd92ae0","acronym":"KEYNOTE-C14","url":"https://clinicaltrials.gov/study/NCT04986852","created_at":"2021-08-03T19:53:05.457Z","updated_at":"2025-02-25T16:16:33.499Z","phase":"Phase 2","brief_title":"Olinvacimab With Pembrolizumab in Patients With mTNBC","source_id_and_acronym":"NCT04986852 - KEYNOTE-C14","lead_sponsor":"PharmAbcine","biomarkers":" HER-2 • ER • PGR • CD4","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • olinvacimab (TTAC-0001)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/30/2021","start_date":" 09/30/2021","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 08/30/2026","study_completion_date":" 08/30/2026","last_update_posted":"2023-11-16"},{"id":"2a9b6465-d0a1-4c1a-9162-4f7490b8b712","acronym":"","url":"https://clinicaltrials.gov/study/NCT03720431","created_at":"2021-01-18T18:14:05.008Z","updated_at":"2024-07-02T16:36:05.322Z","phase":"Phase 1b","brief_title":"TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer","source_id_and_acronym":"NCT03720431","lead_sponsor":"PharmAbcine","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • olinvacimab (TTAC-0001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 01/03/2019","start_date":" 01/03/2019","primary_txt":" Primary completion: 03/18/2020","primary_completion_date":" 03/18/2020","study_txt":" Completion: 10/26/2022","study_completion_date":" 10/26/2022","last_update_posted":"2022-08-17"}]